RNA Editing Enzyme and Methods of Use Thereof

Tech ID
NK-9480
Background

The ADAR (adenosine deaminase that acts on RNA) enzyme, previously known as DRADA, is involved in the RNA editing of glutamate-gated ion channels and the serotonin-2C receptor. This novel enzyme is implicated in central nervous system disorders characterized by abnormal neuronal transmission and intracellular signaling in mammalian brain such as stroke, schizophrenia, depression, and substance abuse.

Key Words
Diagnostic, glutamate, immunoassay, neurological disease, psychiatric disease, research tool, screening, serotonin, Therapeutic
Applications and Advantages

Wistar researchers have identified an ADAR protein that may be useful for the development of diagnostics and therapeutics for managing conditions associated with glutamate-gated ion channel defects or serotonin receptor defects. Potential applications of ADAR include:

  • Screening assays for novel central nervous system therapeutic agents,
  • Diagnostic assays, using anti-ADAR antibodies developed at Wistar,
  • Generation of therapeutic agents for stroke, depression, schizophrenia or substance abuse.
Intellectual Property Status

U.S. Patent Nos. 5,643,778; 5,677,428 and 5,763,174.

Licensing Opportunity

This technology is available for licensing for development of diagnostic or therapeutic agents. Additionally, antibodies to ADAR are available for licensing for research use.